Katharina Robichon

Katharina Robichon

Auto-generated profile, based on publicly available information

Katharina Robichon

Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SMSeeseei Molimau-Samasoni
Seeseei Molimau-Samasoni
VWVictoria Helen Woolner
Victoria Helen Woolner
SFSu’eMalo Talie Foliga
Su’eMalo Talie Foliga
KRKatharina Robichon
Katharina Robichon
VPVimal Patel
Vimal Patel
AMAndrew Munkacsi
Andrew Munkacsi
Significance: Medicinal plants with extensive ethnobotanical histories, particularly those from Asia, have contributed to the approval of natural compounds as pharmaceutical drugs. In contrast, Samoan traditional medicine is relatively understudied. Working with traditional healers via an ethical, data sovereignty–driven collaboration led by indigenous Samoan researchers, we elucidate the chemical biology of the poorly understood but often-used Samoan traditional medicine “matalafi,” the homogenate of Psychotria insularum leaves commonly used to treat inflammation-associated illnesses. Our approach unifies genomics, metabolomics, analytical biochemistry, immunology, and traditional knowledge to delineate the mode of action of the traditional medicine rather than by the more common reductionist approach of first purifying the bioactive principles, which can be used to better understand the ethnobotany of traditional medicine.

1 October 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KRKatharina Robichon
Katharina Robichon
TMTim Maiwald
Tim Maiwald
MSMarcel Schilling
Marcel Schilling
ASAnnette Schneider
Annette Schneider
JWJoschka Willemsen
Joschka Willemsen
UKUrsula Klingmüller
Ursula Klingmüller
The induction of an interferon-mediated response is the first line of defense against pathogens such as viruses. Yet, the dynamics and extent of interferon alpha (IFNα)-induced antiviral genes vary remarkably and comprise three expression clusters: early, intermediate and late. By mathematical modeling based on time-resolved quantitative data, we identified mRNA stability as well as a negative regulatory loop as key mechanisms endogenously controlling the expression dynamics of IFNα-induced antiviral genes in hepatocytes. Guided by the mathematical model, we uncovered that this regulatory loop is mediated by the transcription factor IRF2 and showed that knock-down of IRF2 results in enhanced expression of early, intermediate and late IFNα-induced antiviral genes. Co-stimulation experiments with different pro-inflammatory cytokines revealed that this amplified expression dynamics of the early, intermediate and late IFNα-induced antiviral genes can also be achieved by co-application of IFNα and interleukin1 beta (IL1β). Consistently, we found that IL1β enhances IFNα-mediated repression of viral replication. Conversely, we observed that in IL1β receptor knock-out mice replication of viruses sensitive to IFNα is increased. Thus, IL1β is capable to potentiate IFNα-induced antiviral responses and could be exploited to improve antiviral therapies. Innate immune responses contribute to the control of viral infections and the induction of interferon alpha (IFNα)-mediated antiviral responses is an important component. However, IFNα induces a multitude of antiviral response genes and the expression dynamics of these genes can be classified as early, intermediate and late. Here we show, based on a mathematical modeling approach, that mRNA stability as well as the negative regulator IRF2 control the expression dynamics of IFNα-induced antiviral genes. Knock-down of IRF2 resulted in the amplified IFNα-mediated induction of the antiviral genes and this amplified expression of antiviral genes could be functionally mimicked by co-stimulation with IFNα and IL1β. We observed that co-stimulation with IFNα and IL1β enhanced the repression of virus replication and that knock-out of the IL1 receptor in mice resulted in increased replication of a virus sensitive to IFNα. In sum, our studies identified IL1β as an important amplifier of IFNα-induced antiviral responses.

23 September 2025 in Cytometry Part A
Verified
Journal Article
Open access
KRKatharina Robichon
Katharina Robichon
JTJennifer Taylor
Jennifer Taylor
IMImogen Milner
Imogen Milner
KHKathryn Elizabeth Hally
Kathryn Elizabeth Hally
AFAnne Camille La Flamme
Anne Camille La Flamme
Multiple sclerosis (MS) is a chronic, immune‐mediated autoimmune disease characterized by the infiltration of autoreactive T cells and other inflammatory immune cells from the periphery into the central nervous system. Currently, there is no cure for MS, and treatment consists of disease‐modifying therapies (DMTs), most of which modify or delete specific immune cell populations. These populations express crucial MS treatment‐associated receptors, which may be differentially expressed in each patient, and thus each drug may affect individuals differently. Here, we developed the first comprehensive 24‐parameter flow cytometry immunophenotyping panel to evaluate treatment‐associated receptor expression on the major MS‐associated immune cells in whole blood. Analyzing whole blood samples from treatment‐naïve individuals with MS using this panel, we demonstrated that expression levels of these receptors vary between individuals. Response to the chosen DMT treatment also differed across participants. When monitoring the receptor expression during the course of treatment, we detected an increased response to treatment when receptor expression was elevated at the start of treatment. This panel reliably detects these receptors in MS treatment‐naïve participants and enables monitoring of their expression throughout treatment. This tool will enable deep interrogation of the immune receptors targeted by MS therapies and highlights that treatment‐associated receptor expression levels might be used to predict or correlate with treatment response.

10 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KRKatharina Robichon
Katharina Robichon
TMTim Maiwald
Tim Maiwald
MSMarcel Schilling
Marcel Schilling
ASAnnette Schneider
Annette Schneider
JWJoschka Willemsen
Joschka Willemsen
UKUrsula Klingmüller
Ursula Klingmüller
The induction of an interferon-mediated response is the first line of defense against pathogens such as viruses. Yet, the dynamics and extent of interferon alpha (IFNα)-induced antiviral genes vary remarkably and comprise three expression clusters: early, intermediate and late. By mathematical modeling based on time-resolved quantitative data, we identified mRNA stability as well as a negative regulatory loop as key mechanisms endogenously controlling the expression dynamics of IFNα-induced antiviral genes in hepatocytes. Guided by the mathematical model, we uncovered that this regulatory loop is mediated by the transcription factor IRF2 and showed that knock-down of IRF2 results in enhanced expression of early, intermediate and late IFNα-induced antiviral genes. Co-stimulation experiments with different pro-inflammatory cytokines revealed that this amplified expression dynamics of the early, intermediate and late IFNα-induced antiviral genes can be mimicked by co-application of IFNα and interleukin1 beta (IL1β). Consistently, we found that IL1β enhances IFNα-mediated repression of viral replication. Conversely, we observed that in IL1β receptor knock-out mice replication of viruses sensitive to IFN is increased. Thus, IL1β is capable to potentiate IFNα-induced antiviral responses and could be exploited to improve antiviral therapies. Author Summary: Innate immune responses contribute to the control of viral infections and the induction of interferon alpha (IFNα)-mediated antiviral responses is an important component. However, IFNα induces a multitude of antiviral response genes and the expression dynamics of these genes can be classified as early, intermediate and late. Here we show, based on a mathematical modeling approach, that mRNA stability as well as the negative regulator IRF2 control the expression dynamics of IFNα-induced antiviral genes. Knock-down of IRF2 resulted in the amplified IFNα-mediated induction of the antiviral genes and this amplified expression of antiviral genes could be mimicked by co-stimulation with IFNα and IL1β. We observed that co-stimulation with IFNα and IL1β enhanced the repression of virus replication and that knock-out of the IL1 receptor in mice resulted in increased replication of a virus sensitive to IFNα. In sum, our studies identified IL1β as an important amplifier of IFNα-induced antiviral responses.

17 December 2025 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
SSSven Sondhauss
Sven Sondhauss
MKMackenzie Kiernan
Mackenzie Kiernan
JMJulia Morizzi
Julia Morizzi
PWPhil Wright
Phil Wright
TPThomas E. Prisinzano
Thomas E. Prisinzano
AFAnne Camille La Flamme
Anne Camille La Flamme

13 October 2026 in Seminars in Immunopathology
Verified
Journal Article
Open access
PDF file
KRKatharina Robichon
Katharina Robichon
Rebecca GraingerRebecca Grainger
Rebecca Grainger
Temperature extremes linked to climate change are becoming more frequent and more intense. This has significant implications for human health, including conditions driven by immune dysregulation. There is growing evidence that external thermal stress, particularly heat, may influence both the development and clinical course of several autoimmune conditions. Heat and cold can alter immune cell function through effects on cell signalling, cytokine production, barrier integrity and stress response within tissues. These mechanisms provide a strong biological basis for the observed associations between seasonal or regional temperature patterns and rates of autoimmune disease onset, symptoms, or flare frequency. Temperature extremes present considerable specific health risk to people with autoimmune disease with examples including heat waves worsening fatigue and neurological symptoms in people with multiple sclerosis and cold spells triggering blood vessel constriction and extremity tissue necrosis in systemic sclerosis. As climate instability increases, people with autoimmune disease will face higher clinical risk, due to disease-related factors and increased risks from cardiovascular related morbidity and mortality and concomitant demographic and socio-economic factors. This highlights the need for climate-aware healthcare, patient education, and research that addresses the interface of environmental factors with immune and clinical outcomes.